Association of angiogenic factors with prognosis in esophageal cancer
Authors:
- Lena DreikhausenLDLena Dreikhausen
- Susanne BlankSBSusanne Blank
- Leila SisicLSLeila Sisic
- Ulrike HegerUHUlrike Heger
- Wilko WeichertWWWilko Weichert
- Dirk JägerDJDirk Jäger
- Thomas BrucknerTBThomas Bruckner
- Natalia GieseNGNatalia Giese
- Lars GrenacherLGLars Grenacher
- Christine FalkCFChristine Falk
- Katja OttKOKatja Ott
- Thomas SchmidtTSThomas Schmidt
Open Access
- 13 March 2015
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 121
Abstract
Despite multimodal therapy esophageal cancer often presents with poor prognosis. To improve outcome, tumor angiogenesis and anti-angiogenic therapeutic agents have recently gained importance. However, patient subgroups who benefit from anti-angiogenic therapy are not yet defined. In this retrospective exploratory study we investigated 9 angiogenic factors in patients’ serum and tissue samples with regard to their association with clinicopathological parameters, prognosis and response in patients with locally advanced preoperatively treated esophageal cancer. From 2007 to 2012 preoperative serum and corresponding tumor tissue (n = 54), only serum (n = 20) or only tumor tissue (n = 4) were collected from esophageal squamous cell carcinoma (SCC) (n = 34) and adenocarcinoma of the esophagogastric junction (AEG) (n = 44) staged cT3/4NanyM0/x after preoperative chemo(radio)therapy. Angiogenic cytokine levels in both tissue and serum were measured by multiplex immunoassay. Median survival in all patients was 28.49 months. No significant difference was found in survival between SCC and AEG (p = 0.90). 26 patients were histopathological responders. Histopathological response was associated with prognosis (p = 0.05). Angiogenic factors were associated with the following clinicopathological factors: tumor tissue expression of Angiopoietin-2 and Follistatin was higher in SCC compared to AEG (p = 0.022 and p = 0.001). High HGF and Follistatin expression in the tumor tissue was associated with poor prognosis in all patients (p = 0.037 and p = 0.036). No association with prognosis was found in the patients’ serum. Neither patients’ serum nor tumor tissue showed an association between angiogenic factors and response to neoadjuvant therapy. Two angiogenic factors (HGF and Follistatin) in posttherapeutic tumor tissue are associated with prognosis in esophageal cancer patients. Biological differences of AEG and SCC with respect to angiogenesis were evident by the different expression of 2 angiogenic factors. Results are promising and should be pursued prospectively, optimally sequentially pre- and posttherapeutically.Keywords
This publication has 42 references indexed in Scilit:
- Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosisGastric Cancer, 2013
- TGFβ1 and HGF protein secretion by esophageal squamous epithelial cells and stromal fibroblasts in oesophageal carcinogenesisOncology Letters, 2013
- IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagusMolecular Cancer, 2013
- Targeting Angiogenesis in Esophagogastric AdenocarcinomaThe Oncologist, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Serum follistatin in patients with prostate cancer metastatic to the boneClinical & Experimental Metastasis, 2010
- Mechanisms of Resistance to Anti-Angiogenic Therapy and Development of Third-Generation Anti-Angiogenic Drug CandidatesGenes & Cancer, 2010
- Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinomaBritish Journal of Cancer, 2008
- Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trialEuropean Journal of Surgical Oncology, 2004
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996